Feedback
Settings

Settings

Goto Application

255,844 results
Offices all Languages Stemming true Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K35/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 25,585
1.WO/2025/140504T CELL RECEPTOR TARGETING POLYPEPTIDE WITH KRAS G12V MUTATION AND USE OF T CELL RECEPTOR
WO - 03.07.2025
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
 Appl.No PCT/CN2024/143046 Applicant IMMUXELL BIOTECH LTD. Inventor HU, Hong-Ming
Provided in the present invention are a T cell receptor targeting a polypeptide with a KRAS G12V mutation and the use of the T cell receptor. The T cell receptor molecule of the present invention specifically targets the KRAS G12V mutation, and the CDR3 sequence of the α chain variable region of the T cell receptor molecule contains CAVNPNTGNQFYF (SEQ ID NO: 1) or a mutant of SEQ ID NO: 1, and/or the CDR3 sequence of the β chain variable region contains CASSQDYGPQETQYF (SEQ ID NO: 2) or a mutant of SEQ ID NO: 2. Further provided in the present invention are a nucleic acid molecule encoding the T cell receptor molecule, a multivalent complex and dual-targeting protein molecule containing the T cell receptor molecule, a nucleic acid construct, a cell expressing the T cell receptor molecule, etc.
2.WO/2025/138225MITOCHONDRIAL TRANSPLANTATION THERAPY SYSTEM AND USE THEREOF
WO - 03.07.2025
Int.Class A61K 35/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
 Appl.No PCT/CN2023/143578 Applicant GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES Inventor LIU, Xingguo
The present disclosure relates to the technical field of biomedical materials, and in particular, to a mitochondrial transplantation therapy system and use thereof. The mitochondrial transplantation therapy system provided by the present disclosure comprises: mitochondria obtained by isolation; and a transfer carrier. The mitochondrial transplantation therapy system is obtained by assembling the mitochondria and the transfer carrier. The transfer carrier comprises at least one of an artificial lipid vesicle, a vesicle derived from a cell membrane, and an exosome. The mitochondrial transplantation therapy system has a simple preparation process, and enables efficient and rapid delivery of healthy mitochondria into cells or tissues at the same time, thereby repairing the mitochondrial function of mitochondria-damaged cells. The mitochondrial transplantation therapy system has the potential to treat related diseases caused by mitochondrial dysfunction.
3.WO/2025/143685LEUCONOSTOC FALKENBERGENSE LBMB321010 STRAIN, AND COMPOSITION COMPRISING SAME FOR PREVENTING, ALLEVIATING OR TREATING DEGENERATIVE BRAIN DISEASES
WO - 03.07.2025
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
 Appl.No PCT/KR2024/020751 Applicant LISCURE BIOSCIENCES INC. Inventor CHIN, Hwa Sup
The present invention relates to a Leuconostoc falkenbergense LBMB321010 strain, and a composition comprising same for preventing, alleviating or treating degenerative brain diseases. The strain exhibits excellent preventive and therapeutic effects on various degenerative brain diseases, and thus can be effectively utilized in a composition for a use of treating, preventing or alleviating degenerative brain diseases in humans or animals.
4.WO/2025/140679A LIVE BACTERIA STRAIN OF STAPHYLOCOCCUS SP.
WO - 03.07.2025
Int.Class C12N 1/21
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
 Appl.No PCT/CN2024/143562 Applicant SHANGHAI YUGUAN BIOTECH CO., LTD. Inventor ZHANG, Mengya
Provided are a live bacteria strain of Staphylococcus sp., such as a live bacteria strain of Staphylococcus aureus, with reduced activity of saePQRS, reduced activity of adsA, and/or reduced production of capsules; the uses of said live bacteria strain; a vaccine against bacterial infection comprising said live bacteria strain; and a method for preventing and/or treating bacterial infection in a subject by administering said live bacteria strain.
5.WO/2025/144085METHOD FOR TREATING PAIN
WO - 03.07.2025
Int.Class A61K 36/25
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
 Appl.No PCT/RU2024/050306 Applicant KOSMODEMIANSKII, Leonid Vladimirovich Inventor KOSMODEMIANSKII, Leonid Vladimirovich
The invention relates to medicine, and more particularly to algology, and can be used in the treatment of pain. The present method includes oral administration of a pharmaceutical composition. Administration begins with a minimum single dose comprising: 1 drop or granule of the composition, dissolved in 15 ml of water, per 10 kg of the patient’s weight. The minimum single dose is administered every 15 minutes. An individually tailored single dose is determined by adding up the minimum doses of the composition which induce a subjective sensation of a decrease in pain. The composition is administered in the individually tailored single dose at a dosage frequency of not more than 8 times a day on the first day and not more than four times a day on the second and subsequent days. The pharmaceutical composition contains equal quantities of Eupatorium perfoliatum in a 3D dilution, China officinalis, Secale comutum, Arnica montana in a 3C dilution, Rhus toxicodendron in a 4C dilution, Aconitum napellus, Belladonna, Bryonia alba, Ipecacuanha, Nux vomica in a 5C dilution, Mercurius solubilis in a 6C dilution, Abrotanum, Gallicum acidum, Heloderma suspectum, Senecio aureus in a 7C dilution, and Stramonium in a 9C dilution. The invention provides for a significant decrease in the pain sensations experienced by the patient, irrespective of the source of and reasons for the pain.
6.202025000818Hautcreme aus Rinderschmalz und Rinderknochenmark
DE - 03.07.2025
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
 Appl.No 202025000818 Applicant Carnitarier UG (haftungsbeschränkt) Inventor

Der Schutzanspruch besteht in der Herstellung einer Hautcreme, welche ausschließlich aus Rinderschmalz und Rinderknochenmark besteht.

7.WO/2025/145016CORNEAL ENDOTHELIAL CELL (CEC) CULTURING METHODS AND COMPOSITIONS
WO - 03.07.2025
Int.Class C12N 5/079
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
079Neural cells
 Appl.No PCT/US2024/062074 Applicant AURION BIOTECH, INC. Inventor LACOSTE, Arnaud
Provided herein are methods and compositions for culturing corneal endothelial cells (CECs) to increase the number of cells that may be expanded from a single corneal donor. The resulting compositions can be used in CEC therapies to treat corneal endothelial diseases.
8.WO/2025/144762REPROGRAMMED CELL MODULATION OF CANCER MICROENVIRONMENT BY TUMOR HOMING PERSONALIZED REGENERATIVE CELLS
WO - 03.07.2025
Int.Class C12N 5/0775
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
077Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
0775Mesenchymal stem cells; Adipose-tissue derived stem cells
 Appl.No PCT/US2024/061565 Applicant IMMORTA BIO, INC. Inventor ICHIM, Thomas, E.
Disclosed are methods of augmenting efficacy of oncology therapies by providing reprogrammed cells such as personalized regenerative cells that modulate the tumor microenvironment. In one embodiment, somatic cells are dedifferentiated into OCT-4 expressing cells and endowed with tumor homing properties through culture or gene engineering. Once a stable population of tumor homing cells is established, such cells are made to express immune stimulating agents constitutively, or selectively upon entering the cancer microenvironment. Selective expression of immune stimulatory agents can be induced by exposure to hypoxia, acidosis, immune suppressive signaling or inflammatory signaling.
9.WO/2025/142932COMPOSITION CONTAINING EXTRACELLULAR VESICLES DERIVED FROM MICROALGAE
WO - 03.07.2025
Int.Class A61K 36/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
02Algae
 Appl.No PCT/JP2024/045706 Applicant ROHTO PHARMACEUTICAL CO., LTD. Inventor OKADA,Keita
The purpose of the present invention is to provide a composition that contains extracellular vesicles derived from microalgae and has suppressed discoloration.　In one embodiment of the present invention, a composition containing (A) extracellular vesicles derived from microalgae, (B) a polyhydric alcohol, and (C) at least one chemical selected from the group consisting of organic acids, salts thereof, and nonionic surfactants, is prepared.
10.WO/2025/142752TAL EFFECTOR NUCLEASE PAIR AND USE THEREOF
WO - 03.07.2025
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
 Appl.No PCT/JP2024/045076 Applicant YAHATA Naoki Inventor YAHATA Naoki
The present invention provides a technology capable of more specifically cutting one of mutant mtDNA and wild-type mtDNA. This TAL effector nuclease pair includes a first TAL effector nuclease monomer and a second TAL effector nuclease monomer in which a target sequence is located 12-20 bases apart, and which each include a DNA-binding domain that includes RVDs and that binds to DNA having 8-15 bases, and a DNA cleavage domain of the FokI endonuclease. The RVDs include a first RVD that recognizes a base at the position of a mitochondrial disease-inducing mutation and a second RVD that recognizes a base at a position other than that of the mitochondrial disease-inducing mutation. The first RVD is at least one among NM that recognizes adenine, WK that recognizes guanine, and LK that recognizes guanine. The second RVD recognizes adenine by NI and recognizes guanine by NN.
# -